Oncology & Cancer

Drug combination gets advanced liver cancer patients to surgery

A combination of the kinase-inhibitor drug cabozantinib and the immunotherapy drug nivolumab can make curative surgery possible in some liver cancer patients who would normally not be considered surgery candidates.

Oncology & Cancer

Smart combination therapy for liver cancer tackles drug resistance

Liver cancer is one of the most common cancer types worldwide and is especially common in China. A collaborative effort between researchers at the Netherlands Cancer Institute and Shanghai using CRISPR/Cas has led to the ...

Diseases, Conditions, Syndromes

Tailor-made therapy of multi-resistant tuberculosis

Globally, tuberculosis is the most common bacterial infectious disease leading to death. The pathogen causing tuberculosis, Mycobacterium tuberculosis, has a number of peculiarities. One is that it is growing very slowly. ...

page 6 from 33